DAPT Flashcards
The use of risk scores designed to evaluate the benefits and risks of different DAPT durations may be considered.
PRECISE-DAPT
DAPT
IIb. A
In ACS, ticagrelor 180 mg LD, 90 mg BID on topof aspirin is recommended regardless of initial tratment strategy, including pre-treated with clopidogrel (which should be discontinued when ticagrelor is commenced) unless there are contraindications.
I. B
Due to Plato Trial.
Contraindications for Ticagrelor: Previous intracranial hemorrhage, previous ischemic stroke or transient ischemic attack, ongoing bleeding.
In ACS undergoing PCI, prasugrel (60 mg LD, 10 mg QD) on top of aspirin is recommended for naive patients with NSTE-ACS, STEMI unless there is a high risk of life-threatening bleeding or other contraindications.
I. B.
TRITON TIMI 38.
Contraindications for prasugrel:
Previous hemorrhagic stroke, ischemic stroke or transient ischemic attack, ongoing bleeding,≥ 75 yo, < 60 Kgs.
Pre treatment with P2Y12 inhibitor in generally recommended in patients in whom coronary anatomy is known and the decision to proceed to PCI is made well as in patients with STEMI.
I. A.
PLATO. Ticagrelor
TRITON - TIMI 38. Prasugrel
ATLANTIC. Pre hospital Ticagrelor
In patients with NSTE-ACS undergoing invasive management, ticagrelor administration (180 mg loading dose, 90 mg twice daily), or clopidogrel (600 mg loading dose, 75 mg daily dose) if ticagrelor is not an option, should be considered as soon as the diagnosis is established.
IIa. C
Recommendation of experts.
No trial. In STEMI yes called ATLANTIC
In patients with stable CAD, pre-treatment with clopidogrel may be considered if the probability of PCI is high.
IIb. C
Clopidogrel (600 mg loading dose, 75 mg daily dose) on top of aspirin is recommended in stable CAD patients undergoing coronary stent implantation and in ACS patients who cannot receive ticagrelor or prasugrel, including those with prior intracranial bleeding or indication for OAC.
I. A
